Table 3.
Comparison between the characteristics of patients who underwent re‐biopsy and those who did not
| Characteristics | No re‐biopsy (n = 125) | Re‐biopsy (n = 105) | P (univariate) | Multivariate | |
|---|---|---|---|---|---|
| HR (95% CI) | P | ||||
| Age, years | 69.0 (63.0–75.0) | 65.0 (54.0–73.0) | 0.001 | 0.950 (0.922–0.980) | 0.001 |
| Gender, male | 53 (42.4%) | 56 (53.3%) | 0.235 | ||
| Smoking history | 0.666 | ||||
| Current smoker | 34 (27.2%) | 23 (21.9%) | |||
| Ex‐smoker | 26 (20.8%) | 24 (22.9%) | |||
| Never smoker | 65 (52.0%) | 58 (55.2%) | |||
| ECOG performance status | 0.004 | 4.830 (0.956–24.391) | 0.057 | ||
| 0–2 | 111 (88.8%) | 103 (98.1%) | |||
| 3–4 | 14 (11.2%) | 2 (1.9%) | |||
| Histology | 0.108 | ||||
| ADC | 110 (88.0%) | 99 (94.3%) | |||
| SQC | 12 (11.4%) | 3 (2.9%) | |||
| NSCLC | 2 (1.9%) | 3 (2.9%) | |||
| EGFR‐TKI | 0.006 | 0.106 | |||
| Gefitinib | 69 (55.2%) | 39 (37.1%) | |||
| Erotinib | 54 (43.2%) | 58 (55.2%) | |||
| Afatinib | 2 (1.6%) | 8 (7.6%) | |||
| EGFR mutation status | 0.001 | 0.265 | |||
| 19 deletion and L858R | 58 (44.9%) | 70 (66.0%) | |||
| Others† | 67 (55.1%) | 35 (34.0%) | |||
| Treatment line | 0.058 | ||||
| 1st line | 60 (48.0%) | 65 (61.9%) | |||
| 2nd line | 39 (31.2%) | 33 (31.3%) | |||
| 3rd line | 18 (14.4%) | 5 (4.8%) | |||
| ≥ 4th line | 8 (6.4%) | 2 (2.0%) | |||
| Best response | < 0.0001 | 7.210 (3.203–16.229) | < 0.0001 | ||
| Complete response | 4 (3.2%) | 4 (3.8%) | |||
| Partial response | 48 (38.4%) | 70 (66.7%) | |||
| Stable disease | 27 (21.6%) | 21 (20.0%) | |||
| Progressive disease | 46 (36.8%) | 10 (9.5%) | |||
| Duration of EGFR‐TKIs, days | 131 (55–353) | 348 (172–508) | < 0.0001 | 0.222 | |
†
”Others” includes wild‐type, G719X, uncommon mutations, de novo T790M, and invalid cases.
Values are presented as number (%) or median with interquartile range.
ADC, adenocarcinoma; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NSCLC, non‐small cell lung cancer; SQC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.